HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purged marrows for acute nonlymphocytic leukemia in late remission or early relapse.

Abstract
Twenty-four patients with acute nonlymphocytic leukemia (ANLL) were treated with high-dose chemotherapy or chemoradiotherapy followed by infusion of autologous marrow purged with 100 micrograms/mL of 4-hydroperoxycyclophosphamide (4HC). The marrow harvests were performed when there were less than 5% blasts in the marrow. Seven patients were transplanted in second complete remission (CR), eight in third CR, one in fourth CR, and eight in early relapse. The median time to achieve 500 neutrophils/microL or 1,000 leukocytes/microL was 30 days. A platelet count of 20,000/microL and 50,000/microL was achieved at a median of 67 and 91 days, respectively. One patient failed to engraft by day 58. There were five other transplant-related deaths: sepsis (one), intracerebral hemorrhage (one), veno-occlusive disease (one), and interstitial pneumonia (two). Four of seven evaluable patients transplanted in early relapse obtained a CR lasting 112, 143, 189, and greater than 615 days. Eight of 11 evaluable patients transplanted in CR have relapsed at a median of 153 days (range, 104 to 311). The actuarial survival for all patients was 19%. There was a trend toward improved relapse-free survival for patients transplanted in remission as opposed to those transplanted in relapse (P = .11).
AuthorsC Rosenfeld, R K Shadduck, D Przepiorka, K F Mangan, M Colvin
JournalBlood (Blood) Vol. 74 Issue 3 Pg. 1159-64 (Aug 15 1989) ISSN: 0006-4971 [Print] United States
PMID2665865 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Cyclophosphamide
  • perfosfamide
Topics
  • Actuarial Analysis
  • Adult
  • Blood Cell Count
  • Bone Marrow (drug effects)
  • Bone Marrow Transplantation
  • Child
  • Cyclophosphamide (analogs & derivatives, toxicity)
  • Female
  • Graft Rejection
  • Humans
  • Leukemia, Myeloid, Acute (mortality, surgery)
  • Male
  • Middle Aged
  • Postoperative Complications (blood, mortality)
  • Recurrence
  • Remission Induction
  • Transplantation, Autologous (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: